Sun Pharma Plans $12B Bid For Organon Amid Debt Concerns

Sun Pharmaceutical Industries has moved a step closer to what could become a landmark $12 billion deal, as it prepares a binding offer for Organon & Co.

The Mumbai-based drugmaker has spent over three months on due diligence and is now lining up funding with global lenders. If it goes through, this would be the largest overseas acquisition by an Indian pharma company so far.

The development has also kept Sun Pharmaceutical Industries shares in the spotlight on Dalal Street. The stock has lost about 0.15% since January 1. It experienced lows near ₹1,590 in January, followed by highs of ₹1,800 in March. On 10 April, the stock was down 3.10% at ₹1,663.80 at 9:16 AM on the National Stock Exchange (NSE).

Meanwhile, Organon’s shares have fallen more than 19% this year, reflecting investor caution around its debt and weak growth outlook.

Why Is Sun Pharma Chasing This Deal?

Sun Pharma has been gradually shifting focus from plain generics to more specialised, high-value therapies. Chairman Dilip Shanghvi has spoken about this transition more than once, especially the need to build a pipeline of innovative drugs.

Meanwhile, Organon has an existing portfolio in women’s health, biosimilars, and legacy medicines. Its contraceptive implant Nexplanon remains a key product, even though recent numbers have not been strong.

Sun Pharma has already tested this strategy with smaller deals. Its acquisition of Checkpoint Therapeutics, which brought in an oncology drug, showed where the company wants to go. This potential deal simply scales that ambition.

What Makes Organon A Risky Target?

Organon is carrying heavy debt, close to $8 billion, after being spun off from Merck & Co. in 2021. That burden limits how much the company can invest in growth.

Its business is also under pressure. Some of its older drugs are losing exclusivity, while pricing competition remains intense. In biosimilars, regulatory changes may bring in more competitors, making the space even tighter.

There have also been internal issues. A past probe into sales practices around Nexplanon raised governance concerns. While no financial restatement was needed, it did impact confidence.

Also Read - India’s E-Retail Market To Grow To $180 Billion By 2030 From $66 Billion In 2025

Will The Deal Actually Happen?

However, this is not a one-horse race. Organon is being pursued by multiple bidders, including global investment groups. The company has appointed Morgan Stanley to evaluate offers, which means Sun Pharma will need to stay competitive on both price and structure.

On the funding side, Sun seems prepared. It has a healthy cash position and is working with lenders such as JPMorgan Chase, MUFG, and Standard Chartered to back the bid.

Still, closing the deal is only half the story. The real challenge begins after that. Integrating a business with high debt and limited growth will test execution.

For now, Sun Pharma has made its intent clear. But whether this becomes a breakthrough move or a difficult bet will depend on how the company handles what comes next.

Sources:

Whalesbook

The Economic Times